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ABSTRACT
Genetically modified murine skeletal myoblasts were tissue engineered in vitro into organ-like structures
(organoids) containing only postmitotic myofibers secreting pharmacological levels of recombinant human
growth hormone (rhGH). Subcutaneous organoid implantation under tension led to the rapid and stable ap-
pearance of physiological sera levels of rhGH for up to 12 weeks, whereas surgical removal led to its rapid
disappearance. Reversible delivery of bioactive compounds from postmitotic calls in tissue engineered organs
has several advantages over other forms of muscle gene therapy.
INTRODUCTION
KELETAL MUSCLE IS A PRIMARY TARGET for the delivery ofsystemic therapeutic agents through gene therapy (Blau and
Springer, 1995b) because of its capacity to express foreign DNA
either injected directly as plasmid DNA (Wolff et al., 1990), or
injected as ex vivo-modified myoblasts (Barr and Leiden, 1991 ;
Dhawan et al., 1991). In both instances, the DNA is incorpo-
rated into the host's postmitotic myofibers and results in the
long-term expression and delivery of soluble, bioactive com-
pounds to the circulation. Myoblast gene therapy has success-
fully delivered factors such as growth hormone (Barr and
Leiden, 1991; Dhawan et al., 1991), factor IX (Yao and
Kurachi, 1992), and erythropoietin (Hamamori et al., 1994,
1995), whereas direct intramuscular injection of plasmid DNA
containing the sequence for kallikrein (Xiong et al., 1995) or
kallikrein-binding protein (Ma et al., 1995) leads to the sys-
temic delivery of these blood pressure-regulating molecules.
Several problems currently exist with these gene therapy pro-
tocols. First, the in vivo incorporation of injected plasmid DNA
and myoblasts into host myofibers is variable and inefficient
(Acsadi et al., 1991; Huard et al., 1995), making delivery of a
predetermined level of a bioactive compound difficult. Second,
the foreign DNA can remain dormant for extended periods in
vivo (Yao et al., 1994), or can migrate through the vascular sys-
tem to other sites (Neumeyer et al., 1992). Subsequent surgi-
cal removal of the foreign DNA-containing tissue, if necessary,
would thus be difficult.
Tissue engineering is a new discipline for the in vitro con-
struction of varied tissues such as pancreatic islets, liver, skin,
cartilage, bone, muscle, and blood vessels (Langer and Vacanti,
1993). Although the primary goal of tissue engineering is to re-
place the function of a deficient organ, engineered tissues may
also serve as a vehicle for gene therapy. Skeletal muscle myo-
blasts can be tissue engineered in vitro into organ-like struc-
tures (organoids) containing parallel, postmitotic myofibers
connected to tendon-like structures and organized into fasci-
cles, the functional unit of muscle (Vandenburgh et al., 1991).
Use of these tissue-engineered skeletal muscle organoids for
the systemic delivery of bioactive compounds from foreign
DNA would have advantages over other muscle delivery sys-
tems, including the highly efficient in vitro fusion of myoblasts
into postmitotic myofibers, implantation of only postmitotic
cells, preimplantation monitoring of organoid secretory levels
of the bioactive compound, and reversibility by surgical inter-
vention.
In this report, we describe the use of tissue-engineered skele-
tal muscle organoids for systemic delivery of a bioactive com-
pound. Skeletal muscle organoids containing only postmitotic
myofibers were formed in vitro from genetically modified
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murine myoblasts secreting recombinant human growth hor-
mone (rhGH; Dhawan et al., 1991). When implanted subcuta-
neously into syngeneic mice, the organoids delivered constant
physiological levels of rhGH from the day of implantation out
to 12 weeks. Surgical removal of the implant was easily ac-
complished, and rhGH levels were rapidly decreased. Similar
combined tissue engineering-gene therapy techniques may find
applications in other organs, including bone, lung, blood ves-
sels, skin, and the heart. Part of this work has appeared in ab-
stract form (Vandenburgh et al., 1996).
tached from the silicone rubber mold, and was held at its ends
by the Velco or stainless steel screening. The gel contracted to
form a cylindrical structure approximately 2.5 mm in diameter
by 18 mm in length. After 4-5 days in fusion medium, the
organoids were switched to a maintenance medium (DMEM
with high glucose, 10% horse serum, 5% FCS, and 100 units/ml
penicillin), and treated with 1 izg/ml cytosine arabinoside (araC)
for 4--6 days to remove nonfused proliferating cells. The
organoids were maintained in this maintenance medium for
5-12 days before implantation.
MATERIALS AND METHODS
Tissue engineering murine C2C12 rhGH skeletal
muscle organoids
Murine C2C12 skeletal myoblasts (C2M1XAB) stably trans-
duced with the rhGH gene (Dhawan et al., 1991) were a gift
from Dr. Helen Blau (Stanford University, CA). The rhGH gene
is under control of the retroviral long terminal repeat (LTR)
promoter. The cells also contain the lacZ gene for bacterial/3-
galactosidase (/3-gal) under control of the cytomegalovirus
(CMV) enhancer/ot-globin promoter, allowing histological lo-
calization of the transduced cells. Nontransduced control
C2C12 myoblasts were obtained from the ATCC (Rockville,
MD, cat no. CRLI772). The cells were grown in tissue culture
dishes in growth medium C2GM: Dulbecco's modified Eagles'
medium (DMEM) with high glucose (Life Technologies, Inc.,
Grand Island, NY), 5% fetal calf serum (FCS; Sigma Chem.
Co., St. Louis, MO), 15% defined supplemented calf serum
(Hyclone Laboratories, Inc., Logan, UT), penicillin (100
units/m1, Sigma Chem. Co.), and streptomycin (0.1 mg/ml,
Sigma Chem. Co). Greater than 99% of the C2MIXAB myo-
blasts were positive for/3-Gal, determined by/3-Gal histologi-
cal staining. For organoid formation, myoblasts were harvested
with 0.05% (wt/vol) trypsin, 0.02% (wt/vol) EDTA in Ca 2+
Mg2+-free Earle's balanced salt solution, and pelleted by cen-
trifugation at 1,200 rpm for 4 min. The cells were resuspended
in an ice-cold solution of C2GM containing 1.6 mg/ml colla-
gen (Type I rat tail, Collaborative Biomedical Products,
Bedford, MA) neutralized to pH 7.1 with sterile 0.1 N NaOH
as previously described (Vandenburgh etal., 1988). An ice-cold
solution of MATRIGEL (Collaborative Biomedical Products)
was added to the cell suspension (1:6, vol/vol), and the mix-
ture was immediately cast in molds (0.4 ml/mold containing
1-4 X 10 6 cells) made from silicone rubber tubing (4.8 mm i.d.)
cut lengthwise into 30-mm lengths. Each end of the mold con-
tained a 3-mm x 4-mm piece of either Velcro or stainless steel
screening for organoid attachment (Vandenburgh et al., 1991).
The molds were glued to the bottom of 35-mm tissue culture
dishes. Following casting, the molds were incubated at 37°C
for 2-4 hr to solidify the gel. The gels were then covered with
4 ml of C2GM, incubated for 3-5 days, and the medium was
changed to a myoblast fusion medium for 4 days consisting of
Dulbecco's modified Eagle's medium (DMEM) with high glu-
cose, 2% horse serum (Sigma Chem. Co.), 100 units/ml peni-
cillin. Fusion efficiency in this medium is 75-80%, as deter-
mined by nuclear counting of hematoxylin-eosin stained
cultures (data not shown). After I to 2 days in vitro, the gel de-
Surgical implantation of muscle organoids
Before surgical implantation, the organoids were preincu-
bated at 37°C in DMEM containing 0.125% (wt/vol) bovine
serum albumin for 1 hr. The sides of the rubber mold contain-
ing the organoid were removed with a scalpel so that the
organoid remained attached at its ends in the bottom of the mold
and under tension when implanted. All experimental animals
procedures were approved by the Institutional Animal Care and
Utilization Committee and conformed to the guiding principles
of the American Physiological Society. The breeder stock of
C3HeB/FeJ mice was obtained from Jackson Laboratory (Bar
Harbor, ME). The animals were anesthetized with a mixture of
ketamine (55 mg/kg), promazine (1 mg/kg), and xylazine (5
mg/kg), their backs were shaved and sterilized. A 20- to 30-
mm incision was made along the mid-line, the skin was re-
flected, organoids were inserted under the skin flap, and the
wound sutured closed. Implantation of the organoids is a rapid
procedure (<10 min) and up to four implants can be inserted
into each animal. The mice were injected with 60 mg/kg cy-
closporine A at least I hr before surgery and daily thereafter to
suppress antibody production to rhGH (Behara et al., 1992).
Levels of rhGH were greatest in animals receiving multiple im-
plants, but animal survival was decreased. For the single
organoid implants used in the present study, animal death over
30 days averages 50%. This results from cyclosporine A toxi-
city, because mortality is the same in no-implant cyclosporine
A-treated controls (data not shown).
rhGH radioimmunoassay
A sensitive radioimmunoassay exists for rhGH, which does
not cross-react with murine growth hormone (GH) (Barr and
Leiden, 199 ! ; Dhawan et al., 1991 ) (Nichols Diagnostic Lab,
San Juan Capistrano, CA). The assay is accurate and linear from
0.25 ng/ml to 50 ng/ml. Tissue culture medium aliquots were
assayed directly after a 500-fold dilution. Because C2CI2 cells
do not metabolize rhGH in tissue culture (Barr and Leiden,
1991), medium levels represent accumulated rhGH secretion.
In contrast, rhGH turns over rapidly in vivo (half life < 10 min;
Strobl and Thomas, 1994), and undiluted serum rhGH mea-
surements from animal tail bleeds serve as a real-time assay for
rhGH secretion from the implants.
Histological staining techniques
The differentiated organoids were fixed in IX HISTO-
CHOICE (Amresco, Solon, OH) for 15-30 rain, rinsed with
phosphate-buffered saline (PBS), and immunologically stained
(Vandenburgh et al., 1991) with an antibody against sarcom-
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PLATE 1. Tissue-engineered skeletal muscle organoids with
organized myofibers. C2MIXAB myoblasts suspended in an ex-
tracellular matrix gel are cast in silicone rubber molds and
grown under tension for 2-3 weeks in vitro. Low-power (A)
and high-power (B) whole-mount photographs show the longi-
tudinal alignment of sarcomeric tropomyosin-stained myo-
fibers. The inset in A is a 48-hr postplating unstained organoid
in the casting mold and attached at its ends to stainless steel
screening. Detachment of these organoids at one end causes
them to contract to one-third their length within 12 hr, indicat-
ing the large internal tensions in the tissue. Bars represent 250
/zm, 6 mm, and 20/zm in A, A inset, and B, respectively.
PLATE 3. Post-mitotic myofibers in subcutaneously im-
planted muscle organoids survive in vivo. Muscle organoids im-
planted for 2 weeks in vivo are surgically removed, fixed in
0.25% buffered glutaraldehyde, embedded, and frozen in liquid
nitrogen for cryostat sectioning. A. Ten-micrometer cryostat
cross section of the organoid with large-well differentiated and
oriented myofibers under a host-formed epimysium (arrow).
Hematoxylin and eosin stained. B. Ten-micrometer cryostat
cross section stained for fl-Gal shows heavily stained
myofibers also containing the rhGH gene. Bars in A and B rep-
resent 8/xm.
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PLATE 2. Delivery of rhGH from tissue engineered muscle organoids is a rapidly reversible procedure. A. A 40-day subcu-
taneous implanted organoid retains its morphologically distinct structure. The silicone rubber mold that holds the organoid un-
der tension in vivo is removed for the photograph. The black Velcro end pieces to which the organoid is attached are indicated
by arrows. The reddish color of the implant indicates that it is well vascularized. B. Six animals are implanted with rhGH-se-
creting muscle organoids and on days 6-7 post-implant, implants are surgically removed (at R on graph) from 3 animals. C on
the graph is an animal implanted with a control non-rhGH-secreting C2C12 organoid. Each line represents an individual animal.
Similar results were obtained in two additional experiments.
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eric tropomyosin (Sigma Chem. Co.). This was followed by an
avidin-biotinylated secondary antibody coupled to horseradish
peroxidase (Vectastain, Vector Laboratories, Burlingame, CA)
and development with diaminobenzidine to form a brown pre-
cipitate. For fl-Gal staining, organoids were fixed for 10-15
min in 0.25% glutaraldehyde, rinsed with PBS, and incubated
overnight at 4°C in 30% (wt/vol) sucrose in PBS. The organoids
were placed in TISSUE-TEK OTC Embedding Medium (Miles,
Inc., Elkhart, IN) and frozen to -20°C; 10-/_m cryostat sec-
tions were cut. A HISTOMARK X-Gal Substrate Kit was used
according to the manufacturer's recommendations (Kirkegaard
and Perry Laboratories, Inc. Gaithersburg, MD).
RESULTS AND DISCUSSION
Skeletal muscle organoids are formed from C2MIXAB myo-
blasts after suspending in a solution of Type l collagen-MA-
TRIGEL and casting the cell-gel mix in semicircular molds with
the gross morphology of a skeletal muscle. High internal lon-
gitudinal tensions are generated in the gels as they dehydrate
(Bell et al., 1979), causing detachment from the mold surface
and formation of a cylindrical structure attached only at its ends
(Plate IA, inset). These matrix tensions are adequate for align-
ing the fusing myoblasts into parallel arrays of myofibers ex-
pressing sarcomeric tropomyosin (Plate 1). Histological analy-
sis of 2- to 3-week-old organoids shows a thick layer of
well-differentiated, longitudinally oriented myofibers on the
surface of the organoids, and a central core of extracellular ma-
trix containing a low density of short two- to four-nuclei un-
oriented myofibers (data not shown). The surface myofibers are
one to six cell layers deep (0.18 - 0.03 mm thick), whereas the
central connective tissue core is 2.40 _ 0.18 mm in diameter
(mean - SE, n = 4). AraC (i /aM for 4--6 days) is effective in
killing 99.4--+ 0.2% (mean _ SE, n = 4) of the unfused
C2MIXAB myoblasts, determined quantitatively on hema-
toxylin and tropomyosin-stained cultures (Vandenburgh et al.,
1995).
The differentiated organoids secrete consistent levels of
rhGH into their culture medium for several weeks, ranging from
1.0 to 2.9 p,g of rhGH/24 hr per organoid (n = 82). This equals
a production rate of 7-20 ng/l 0 rain per organoid. Cytosine ara-
binoside treatment reduces rhGH secretion by 18% (p < 0.01,
n = 8) as would be expected with a myoblast fusion efficiency
of 80%, and equivalent levels of rhGH secretion per nucleus in
unfused myoblasts and myofibers (Dhawan et al., 1991). The
rhGH secreted by the differentiated organoids comes from post-
mitotic myofibers in which all of the myofiber nuclei contain
the rhGH DNA, rather than a small subset of nuclei as occurs
in the in vivo plasmid DNA and myoblast injection techniques.
Two- to three-week-old organoids secreting consistent
amounts of rhGH are implanted (one/animal) under tension sub-
cutaneously into the backs of 4- to 6-week-old C3HeB/FeJ mice
syngeneic for the C2C12 cell line. In eight separate experi-
ments, 32 of 45 animals survived the surgery for at least 72 hr.
Of the 32 survivors, 27 produced constant physiological serum
levels of rhGH (al-Hendy et al., 1995), ranging from 0.5 to 3.5
ng/ml, from 24 hr to 10-14 days post-implantation (Fig. 1A).
These rhGH levels are similar to those obtained with either di-
rect intramuscular C2MIXAB myoblast injections (Dhawan et
al., 1991), or when rhGH-secreting primary fibroblasts are in-
jected under the renal capsule (Heartlein et al., 1994). Assuming
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FIG. 1. Organoids containing post-mitotic C2MIXAB myofibers secrete physiological levels of rhGH when implanted under
tension in vivo. A. Muscle organoids (one/animal) are implanted subcutaneously under tension into 4- to 6-week-old syngeneic
HeB/FeJ mice at day 0 and sera levels of rhGH measured by radioimmunoassay (RIA). Each line represents an individual ani-
mal. Non-rhGH-secreting control organoids are formed from normal C2C12 myoblasts and implanted in an identical fashion. B.
Weekly rhGH serum levels for animals implanted subcutaneously under tension with one organoid/animal. Values are means _
SE for n = 25 (week 1) to n = 5 (week 12). There are no significant differences (p > 0.5) between week 1 and week 12 values
(paired t-test, n = 5). C. Organoids implanted under no tension (day 0) produce similar levels of rhGH to organoids implanted
under tension for 9 days in vivo, but by 60 days the secretion levels from no-tension implants are decreased compared to organoids
implanted under tension. Bars are means ±SE. A second experiment of this type gave similar results.
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a mean half-life of 10 min for rhGH in vivo (Strobl and Thomas,
1994), it can be calculated that 28-30% of the rhGH produced
by the organoids in vitro appears in the blood within 24 hr of
implantation. These results imply that subcutaneous organoid
implantation is an efficient site for rhGH delivery. Organoids
continue to produce consistent levels of rhGH for 10--I 2 weeks
in vivo, without any significant change from the secretion lev-
els seen at ! week (Fig. IB). Week-to-week variations in rhGH
levels were noted in the same animals (approximately two- to
three-fold, e.g., closed circle-solid line animal in Plate 2B) from
2 weeks to 12 weeks post implantation and may result from
host regulation of rhGH transcription, translation, and/or se-
cretion from the muscle fibers (Crystal, 1995). The consistent
release of rhGH from the organoids is in marked contrast to
rhGH secretion resulting from intramuscularly injected
C2MIXAB myoblasts, where a 10- to 15-fold variation in serum
rhGH levels occurs during the 12 weeks following injection
(Dhawan et al., 1991). The delivery of rhGH from organized
postmitotic myofibers also appears to have advantages over its
delivery from collagen-embedded proliferating, genetically
modified fibroblasts, where reduced secretion with time results
in a 95% loss in serum levels by 42 days in vivo (Chen et al.,
1995).
Maintaining the implanted organoids under tension is im-
portant for optimal long-term secretion of rhGH. Implantation
of organoids under no tension results in a 77% reduction (p <
0.05) in serum rhGH levels after 60 days in vivo compared to
organoids implanted under tension (Fig. 1C). Loss of tension
on organoid myofibers in vitro leads to significant myofiber at-
rophy, indicated by a 35% loss in organoid cellular proteins af-
ter 6 days of tension release (n = 4, p < 0.01). It has been re-
ported by others that injection of myoblasts and disorganized
myofibers provides a better bioactive compound delivery sys-
tem than injection of myoblasts only (Jiao et al., 1993), possi-
bly because of the greater protein synthesis capacity of post-
mitotic muscle fibers compared to myoblasts. Prevention of
myofiber atrophy in organoid structures by maintaining them
under tension following implantation as done in the present
study would further enhance the myofibers' large protein syn-
thetic capability.
The systemic delivery of rhGH from the skeletal muscle
organoids is a reversible procedure. For certain cell-based de-
livery techniques such as for bone repair (Fang et al., 1996) or
wound healing (Blau and Springer, 1995a), implant removal af-
ter healing may be desirable. The muscle organoids are rapidly
encapsulated by host fibroblasts and vascularized when im-
planted subcutaneously, but they maintain their gross in vitro
structure separate from the host (Plate 2A), and are easily re-
moved surgically. Animals from which organoids are removed
shows a rapid decrease in sera rhGH (Plate 2B). Hematoxylin
and eosin staining of cryostat sections of the removed organoids
shows a host-generated epimysium containing numerous fi-
broblast-like cells (Plate 3A). Capillaries are noted in the epimy-
slum but not in the central connective tissue core of the organoid
(data not shown). The myofibers underneath the epimysium are
well-differentiated and maintain their parallel orientation. When
cryostat sections of the removed organoids are histologically
stained for/3-Gal to identify the implanted myofibers, only well-
aligned myofibers are positively stained (Plate 3B). No fl-Gal-
positive, proliferating cells or tumor-like structures are seen in
the mice, as expected with the pretreatment of the organoids
with cytosine arabinoside.
The course of skeletal muscle differentiation in tissue cul-
ture is well established and, in most respects, follows the in
vivo sequence, including the fusion of myoblasts into contrac-
tile myofibers expressing skeletal muscle-specific genes.
Mechanical tension during organogenesis is an important or-
ganizing force in this tissue, and the application of in vivo-like
mechanical forces to differentiating muscle cells in vitro leads
to the formation of an organ-like muscle structure capable of
performing directed functional work (Vandenburgh et al.,
1991). Their use as a delivery system of bioactive molecules
through genetic engineering has additional potential advantages
over other forms of muscle gene therapy. Recent evidence in-
dicates that direct gene transfer by plasmid DNA injection in
vivo may be even more difficult in primates than rodents be-
cause the thicker extracellular matrix around in vivo primate
myofibers may inhibit DNA uptake by the muscle cells (Jiao
et al., 1992). This problem would not exist for the organoid de-
livery technique because insertion of the foreign DNA occurs
before connective tissue formation. Another advantage of the
organoid technique is that only postmitotic cells containing for-
eign DNA are implanted, reducing potential problems associ-
ated with proliferating cell transformation and tumor formation
(Vile and Russell, 1995). Finally, techniques are well estab-
lished for the successful removal and reimplantation of human
skeletal muscle organs during reconstructive surgery and may
be useful for long-term human muscle organoid implantation
into an intramuscular site where it could possibly become in-
nervated.
In summary, this preliminary report describes a new method
for the delivery of physiological levels of a bioactive compound
from organized postmitotic myofibers that combines gene ther-
apy and tissue engineering techniques. Although still facing ma-
jor hurdles before clinically effective therapies are possible
(Crystal, 1995), skeletal muscle delivery systems for gene ther-
apy look promising for future development.
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